Minor Cytological Abnormalities and up to 7-Year Risk for Subsequent High-Grade Lesions by HPV Type.
Maria Persson, K Miriam Elfström, Sven-Erik Olsson...
https://pubmed.ncbi.nlm.nih.gov/26083247/Actively Recruiting
Led by Second Affiliated Hospital, Zhejiang University, School of Medicine · Updated on 2026-10-16
225
Participants Needed
5
Research Sites
47 weeks
Total Duration
Researchers are evaluating the use of ALA-PDT a type of photodynamic therapy compared to observation for treating cervical low-grade squamous intraepithelial lesions LSIL in women infected with HPV types 16 or 18. This prospective, multicenter trial aims to assess the effectiveness and safety of ALA-PDT in this condition. The study also monitors HPV clearance, lesion progression, and patient quality of life. Participants in the treatment group receive ALA-PDT applied to the cervix and cervical canal, followed by light therapy every 7 to 14 days for a total of 3 to 6 sessions. The comparison group undergoes observation and follow-up without active treatment. Both groups are followed over time to evaluate lesion regression and HPV clearance rates. During the study, women will have assessments including colposcopy-guided cervical biopsies to track lesion changes and HPV status over up to two years. Researchers will also monitor safety, tolerability, patient-reported quality of life, and treatment satisfaction. The primary outcome is the rate of cervical lesion regression at 6 months, with additional outcomes measured up to 2 years. The total participation duration extends through the follow-up period until study completion.
CONDITIONS
Multicenter Prospective Non-randomized Controlled Study of ALA-PDT for LSIL With HPV16/18 Infection
X
Xiaoyun Wang, Doctor
J
Jianwei Zhou, Professor
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Second Affiliated Hospital, Zhejiang University, School of Medicine
Lead Sponsor
Women's Hospital School Of Medicine Zhejiang University
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 6 to 12 weeks
Participants either receive ALA-PDT treatment every 7 to 14 days for 3 to 6 sessions or are observed without active treatment during this period.
Regular visits during treatment or observation period
Duration - Up to 2 years
Participants are monitored for lesion regression, HPV clearance, and safety for up to 2 years after treatment or observation.
Periodic follow-up visits
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Maria Persson, K Miriam Elfström, Sven-Erik Olsson...
https://pubmed.ncbi.nlm.nih.gov/26083247/Xiaoyun Wang, Xiaoming Xu, Yaxi Ma...
https://pubmed.ncbi.nlm.nih.gov/38794347/Misako Kusakabe, Ayumi Taguchi, Kenbun Sone...
https://pubmed.ncbi.nlm.nih.gov/37294390/Xiaoyun Wang, Lifang You, Weijiang Zhang...
https://pubmed.ncbi.nlm.nih.gov/35288319/Dongmei Li, Zhichao Wang, Yan Liu...
https://pubmed.ncbi.nlm.nih.gov/39639322/Freddie Bray, Mathieu Laversanne, Hyuna Sung...
https://pubmed.ncbi.nlm.nih.gov/38572751/Lihua Qiu, Jingran Li, Fei Chen...
https://pubmed.ncbi.nlm.nih.gov/35781093/Second Affiliated Hospital, Zhejiang University, School of Medicine
Lead Sponsor
Women's Hospital School Of Medicine Zhejiang University
Collaborating Sponsor